Healthtech Solutions (OTC: HLTT) is positioning itself to be a leader in the burgeoning precision oncology market — projected to grow at a 9.9% CAGR from 2019 to 2027 and reach an estimated $99.7 billion — as a result of its newest acquisition: Varian Biopharmaceuticals. Varian is a precision oncology company developing novel therapeutics for the treatment of cancer — a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types. Its drug candidates, VAR-101 and VAR-102, leverage the company’s expertise. According to HLTT chairman David Rubin, who was quoted by a recent article, “Varian Bio is at the leading edge of cancer treatment, and it is an honor to have them join our portfolio… The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
To view the full article, visit https://ibn.fm/MKKvp
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources on creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- MediScan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceutical Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.